BPC-157 at 0.00068 mg/lb or 0.0000068 mg/lb given before or after each MPTP dose improved somatosensory orientation, reduced hyperactivity and motor abnormalities, and achieved almost complete abolition of MPTP-induced mortality in rats
observed that this may limit gains in fat stores in obese murine models by over 50% (4)
Dosing frequency ranges from daily to three times per week depending on the clinical goal and the patient's response
In many weight loss programs, patients receive a Lipo-B injection about once a week for optimal results
Subcutaneous (SubQ) injections deliver a medication into the fatty tissue just under the skin
MOTS-c has attracted considerable scientific interest because of its role in metabolism, and early human studies have begun, but there is currently insufficient evidence to support its use for obesity or osteoporosis, Dr